$EVFM
Evofem Biosciences, Inc.

2020 Q4 Form 10-Q Financial Statement

#000161883520000242 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $170.0K $278.0K $0.00
YoY Change
Cost Of Revenue $250.0K $317.0K $0.00
YoY Change
Gross Profit -$80.00K -$39.00K $0.00
YoY Change
Gross Profit Margin -47.06% -14.03%
Selling, General & Admin $29.92M $21.90M $8.634M
YoY Change 216.95% 153.65% 0.63%
% of Gross Profit
Research & Development $5.950M $4.217M $5.663M
YoY Change 73.47% -25.53% -42.51%
% of Gross Profit
Depreciation & Amortization $120.0K $60.00K $70.00K
YoY Change 100.0% -14.29% 0.0%
% of Gross Profit
Operating Expenses $35.87M $26.43M $14.30M
YoY Change 178.67% 84.89% -22.44%
Operating Profit -$35.95M -$26.16M -$14.30M
YoY Change 82.95% -22.44%
Interest Expense -$3.670M -$3.080M $210.0K
YoY Change -3158.33% -1566.67% 425.0%
% of Operating Profit
Other Income/Expense, Net -$1.070M -$3.741M $499.0K
YoY Change -790.32% -849.7% 24850.0%
Pretax Income -$40.60M -$29.90M -$13.80M
YoY Change 219.18% 116.68% -25.14%
Income Tax $0.00 $2.000K $0.00
% Of Pretax Income
Net Earnings -$40.60M -$29.90M -$13.80M
YoY Change 219.26% 116.69% -25.14%
Net Earnings / Revenue -23882.35% -10755.04%
Basic Earnings Per Share -$0.37
Diluted Earnings Per Share -$499.3K -$0.37 -$298.4K
COMMON SHARES
Basic Shares Outstanding 81.28M shares 81.21M shares 46.60M shares
Diluted Shares Outstanding 81.21M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.90M $86.70M $35.80M
YoY Change 105.46% 142.18% 195.87%
Cash & Equivalents $48.89M $86.70M $32.12M
Short-Term Investments $0.00 $100.0K $3.700M
Other Short-Term Assets $40.40M $10.50M $1.500M
YoY Change 2026.32% 600.0% 50.0%
Inventory $7.162M $3.164M
Prepaid Expenses
Receivables $1.067M $1.243M
Other Receivables $200.0K $500.0K
Total Short-Term Assets $97.73M $102.1M $37.53M
YoY Change 269.9% 171.98% 179.59%
LONG-TERM ASSETS
Property, Plant & Equipment $4.334M $1.976M $546.0K
YoY Change 1000.0% 261.9% -16.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.048M $1.074M $596.0K
YoY Change -20.61% 80.2% -37.26%
Total Long-Term Assets $12.24M $10.25M $1.457M
YoY Change 553.04% 603.36% -9.05%
TOTAL ASSETS
Total Short-Term Assets $97.73M $102.1M $37.53M
Total Long-Term Assets $12.24M $10.25M $1.457M
Total Assets $110.0M $112.3M $38.99M
YoY Change 288.65% 188.1% 159.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.64M $5.427M $5.163M
YoY Change 77.11% 5.11% -35.74%
Accrued Expenses $4.476M $4.607M $6.453M
YoY Change 60.78% -28.61% -55.33%
Deferred Revenue
YoY Change
Short-Term Debt $52.40M $48.10M $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $77.28M $65.69M $14.91M
YoY Change 510.5% 340.47% -40.44%
LONG-TERM LIABILITIES
Long-Term Debt $25.20M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.100M $6.400M $0.00
YoY Change
Total Long-Term Liabilities $31.30M $6.400M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $77.28M $65.69M $14.91M
Total Long-Term Liabilities $31.30M $6.400M $0.00
Total Liabilities $108.6M $72.12M $14.91M
YoY Change 758.05% 383.55% -40.56%
SHAREHOLDERS EQUITY
Retained Earnings -$655.5M -$614.9M -$500.5M
YoY Change 27.73% 22.86% 19.68%
Common Stock $656.8M $655.1M $524.5M
YoY Change 24.21% 24.89% 28.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.347M $40.21M $24.08M
YoY Change
Total Liabilities & Shareholders Equity $110.0M $112.3M $38.99M
YoY Change 288.65% 188.1% 159.48%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$40.60M -$29.90M -$13.80M
YoY Change 219.26% 116.69% -25.14%
Depreciation, Depletion And Amortization $120.0K $60.00K $70.00K
YoY Change 100.0% -14.29% 0.0%
Cash From Operating Activities -$39.08M -$35.82M -$14.42M
YoY Change 190.56% 148.4% 61.66%
INVESTING ACTIVITIES
Capital Expenditures -$1.420M -$830.0K -$20.00K
YoY Change 914.29% 4050.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $530.0K -$3.720M
YoY Change -100.0% -114.25%
Cash From Investing Activities -$1.420M -$300.0K -$3.740M
YoY Change -69.33% -91.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 24.92M -600.0K -420.0K
YoY Change 1032.73% 42.86% -77.89%
NET CHANGE
Cash From Operating Activities -39.08M -35.82M -14.42M
Cash From Investing Activities -1.420M -300.0K -3.740M
Cash From Financing Activities 24.92M -600.0K -420.0K
Net Change In Cash -15.58M -36.72M -18.58M
YoY Change -1.89% 97.63% 71.72%
FREE CASH FLOW
Cash From Operating Activities -$39.08M -$35.82M -$14.42M
Capital Expenditures -$1.420M -$830.0K -$20.00K
Free Cash Flow -$37.66M -$34.99M -$14.40M
YoY Change 182.95% 142.99% 61.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001618835
CY2020Q2 evfm Class Of Warrant Or Right Vesting Term
ClassOfWarrantOrRightVestingTerm
P5Y
CY2015Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0.001 shares
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0175
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36754
dei Entity Registrant Name
EntityRegistrantName
EVOFEM BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8527075
dei Entity Address Address Line1
EntityAddressAddressLine1
12400 High Bluff Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
550-1900
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
81280286 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86697000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15571000 USD
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
337000 USD
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
304000 USD
CY2020Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
0 USD
CY2019Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
8233000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1243000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
3164000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
0 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10638000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2313000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
102079000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
26421000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1976000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
394000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7198000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
160000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1074000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1320000 USD
CY2020Q3 us-gaap Assets
Assets
112327000 USD
CY2019Q4 us-gaap Assets
Assets
28295000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5427000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6008000 USD
CY2020Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
48055000 USD
CY2019Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4607000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2784000 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4954000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3670000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1728000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
197000 USD
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
921000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
65692000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12659000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6425000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2020Q3 us-gaap Liabilities
Liabilities
72117000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
12659000 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81280286 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81280286 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48137880 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48137880 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
8000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
5000 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
655092000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
528810000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-614890000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-513179000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
40210000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15636000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
112327000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28295000 USD
CY2020Q3 us-gaap Revenues
Revenues
278000 USD
CY2019Q3 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
278000 USD
us-gaap Revenues
Revenues
0 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
317000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
317000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4217000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5663000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11104000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18798000 USD
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14700000 USD
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3791000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
32553000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6222000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7200000 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4843000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24077000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14850000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
26434000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
14297000 USD
us-gaap Operating Expenses
OperatingExpenses
68051000 USD
us-gaap Operating Expenses
OperatingExpenses
39870000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26156000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14297000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-67773000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-39870000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
21000 USD
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
212000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
152000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
338000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-657000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
287000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1010000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
266000 USD
CY2020Q3 evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
0 USD
CY2019Q3 evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
0 USD
evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
64049000 USD
evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
674000 USD
CY2020Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-3105000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15636000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
73000 USD
CY2019Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
0 USD
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
30971000 USD
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-27372000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3741000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
499000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33936000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27442000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29897000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13798000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-101709000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-67312000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-29899000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-13798000 USD
us-gaap Net Income Loss
NetIncomeLoss
-101711000 USD
us-gaap Net Income Loss
NetIncomeLoss
-67316000 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.63
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.83
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
81206101 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46239225 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62434949 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36760013 shares
CY2020Q1 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
-25000 USD
us-gaap Net Income Loss
NetIncomeLoss
-67316000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3401000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-19146000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
1021000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
103266000 USD
CY2020Q2 evfm Stock Issued During Period Value Employee Stock Purchase Plans And Exercise Of Stock Options
StockIssuedDuringPeriodValueEmployeeStockPurchasePlansAndExerciseOfStockOptions
177000 USD
CY2020Q2 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
-2777000 USD
CY2020Q2 evfm Short Swing Profit Disgorgement
ShortSwingProfitDisgorgement
187000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
11015000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6034000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-52666000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
68539000 USD
CY2020Q3 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
-67000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1637000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-29899000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
40210000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-23356000 USD
CY2019Q1 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
-6000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1962000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-18068000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-28851000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
46000 USD
CY2019Q2 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
-518000 USD
CY2019Q2 evfm Adjustments To Additional Paidin Capital Reclassificationof Warrants And Purchase Rights Liability
AdjustmentsToAdditionalPaidinCapitalReclassificationofWarrantsAndPurchaseRightsLiability
29726000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2515000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-35450000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
35792000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
60000 USD
CY2019Q3 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
-122000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2263000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-13798000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
24075000 USD
us-gaap Net Income Loss
NetIncomeLoss
-101711000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
408000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-505000 USD
evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
64049000 USD
evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
674000 USD
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
30971000 USD
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-27372000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
11072000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
6740000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
181000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
198000 USD
us-gaap Lease Cost
LeaseCost
542000 USD
us-gaap Lease Cost
LeaseCost
487000 USD
us-gaap Interest Expense
InterestExpense
992000 USD
us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1243000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2912000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9070000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3628000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2900000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-5186000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1283000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-8000 USD
evfm Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
357000 USD
evfm Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
576000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65750000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41651000 USD
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
250000 USD
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
250000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
8233000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
0 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
0 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
3715000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
833000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7650000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3488000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6273000 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
75400000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
103738000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
867000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
evfm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3781000 USD
evfm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
337000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
46000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25000000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
evfm Proceeds From Short Swing Profit Disgorgement
ProceedsFromShortSwingProfitDisgorgement
187000 USD
evfm Proceeds From Short Swing Profit Disgorgement
ProceedsFromShortSwingProfitDisgorgement
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4010000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1180000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2869000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
645000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129309000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75884000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
73000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
127000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
802000 USD
evfm Deferred Offering Costs Included In Accounts Payable And Accrued Expense
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense
0 USD
evfm Deferred Offering Costs Included In Accounts Payable And Accrued Expense
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense
50000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87834000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32506000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7618000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
71209000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30745000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16625000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1761000 USD
evfm Reclassification Of Warrants And Purchase Rights To Equity
ReclassificationOfWarrantsAndPurchaseRightsToEquity
11015000 USD
evfm Reclassification Of Warrants And Purchase Rights To Equity
ReclassificationOfWarrantsAndPurchaseRightsToEquity
6120000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
103700000 USD
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
86700000 USD
CY2020Q3 evfm Working Capital Surplus Deficit
WorkingCapitalSurplusDeficit
36400000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-614900000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes thereto.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ignificant estimates affecting amounts reported or disclosed in the consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items, the trade accounts receivable credit loss reserve estimate, the discount rate used in estimating the fair value of the lease right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use (ROU) assets and lease liabilities, the assumptions used in estimating the fair value of warrants and purchase rights issued, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, the assumptions used in estimating the fair value of stock-based compensation expense and in assessing the probability of achieving certain milestones associated with the performance-based restricted stock awards. These assumptions are more fully described in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9c04280d63164b869c86c490777daa0c_1196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3- Revenue R</a><a href="#i9c04280d63164b869c86c490777daa0c_1196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">eco</a><a href="#i9c04280d63164b869c86c490777daa0c_1196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">gnition</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9c04280d63164b869c86c490777daa0c_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5- Convertible Notes</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9c04280d63164b869c86c490777daa0c_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7- Fair Value of Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9c04280d63164b869c86c490777daa0c_64" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 8- Commitments and Contingencies</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9c04280d63164b869c86c490777daa0c_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note </a></span></div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9c04280d63164b869c86c490777daa0c_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">12- Stock-based Compensation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by the Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances due to the financial position of the depository institutions in which these deposits are held.</span></div>
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86697000 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32120000 USD
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
337000 USD
CY2019Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
386000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87834000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32506000 USD
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19532661 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19532661 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13182426 shares
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13182426 shares
CY2019Q4 evfm Product Revenue Variable Consideration Contra Asset Current
ProductRevenueVariableConsiderationContraAssetCurrent
0 USD
evfm Product Revenue Variable Consideration Contra Asset Provision For The Current Period
ProductRevenueVariableConsiderationContraAssetProvisionForTheCurrentPeriod
123000 USD
evfm Product Revenue Variable Consideration Contra Asset Credit Or Payment Made
ProductRevenueVariableConsiderationContraAssetCreditOrPaymentMade
-25000 USD
CY2020Q3 evfm Product Revenue Variable Consideration Contra Asset Current
ProductRevenueVariableConsiderationContraAssetCurrent
98000 USD
CY2019Q4 evfm Product Revenue Variable Consideration Liability Current
ProductRevenueVariableConsiderationLiabilityCurrent
0 USD
evfm Product Revenue Variable Consideration Liability Provision For Current Period
ProductRevenueVariableConsiderationLiabilityProvisionForCurrentPeriod
1015000 USD
evfm Product Revenue Variable Consideration Liability Credit Or Payment Made
ProductRevenueVariableConsiderationLiabilityCreditOrPaymentMade
-94000 USD
CY2020Q3 evfm Product Revenue Variable Consideration Liability Current
ProductRevenueVariableConsiderationLiabilityCurrent
921000 USD
CY2020Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
317000 USD
CY2020Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
2441000 USD
CY2020Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
406000 USD
CY2020Q3 us-gaap Inventory Gross
InventoryGross
3164000 USD
CY2020Q2 evfm Securities Sold Under Purchase Agreement
SecuritiesSoldUnderPurchaseAgreement
15000000.0 USD
CY2020Q2 evfm Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement
PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement
10000000.0 USD
CY2020Q2 evfm Purchase Agreement Threshold Amount Of Aggregate Gross Proceeds From Future Sale Of Equity Securities
PurchaseAgreementThresholdAmountOfAggregateGrossProceedsFromFutureSaleOfEquitySecurities
100000000.0 USD
CY2020Q2 evfm Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement
PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement
10000000.0 USD
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.44
CY2020Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
58100000 USD
CY2020Q2 evfm Class Of Warrant Or Right Liability
ClassOfWarrantOrRightLiability
46700000 USD
CY2020Q2 evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
64000000.0 USD
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
800000 USD
CY2020Q2 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
34100000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
15800000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
11000000.0 USD
CY2020Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-3100000 USD
CY2019Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
8233000 USD
CY2019Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
42000 USD
CY2019Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
8275000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10638000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2313000 USD
CY2016Q3 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
1900000 USD
CY2016Q3 us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
600000 USD
CY2016Q3 us-gaap Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net
DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
1300000 USD
CY2016Q3 evfm Disposal Group Including Discontinued Operation Consideration Receivable Stated Rate
DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableStatedRate
0.050
CY2015Q1 evfm Lessee Operating Lease Renewal Options
LesseeOperatingLeaseRenewalOptions
2 renewal_term
CY2016Q3 evfm Disposal Group Including Discontinued Operation Consideration Receivable Annual Principal Payment
DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableAnnualPrincipalPayment
300000 USD
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3006000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1243000 USD
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1030000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
849000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1976000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
394000 USD
CY2019Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
100000 USD
CY2020Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
100000 USD
us-gaap Depreciation Nonproduction
DepreciationNonproduction
200000 USD
us-gaap Depreciation Nonproduction
DepreciationNonproduction
200000 USD
CY2019Q4 evfm Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
585000 USD
CY2020Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1375000 USD
CY2020Q3 evfm Accrued Manufacturing Related Costs Current
AccruedManufacturingRelatedCostsCurrent
1413000 USD
CY2019Q4 evfm Accrued Manufacturing Related Costs Current
AccruedManufacturingRelatedCostsCurrent
0 USD
CY2019Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
0 USD
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1276000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2784000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1652000 USD
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000 USD
CY2020Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
34000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1074000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1320000 USD
CY2020Q3 evfm Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
289000 USD
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
254000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
547000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4607000 USD
CY2020Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
86833000 USD
CY2020Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
47063000 USD
CY2020Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
47063000 USD
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
22588000 USD
CY2020Q2 evfm Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement
PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement
10000000 USD
CY2020Q3 evfm Lessee Operating Lease Number Of Vehicles Leased
LesseeOperatingLeaseNumberOfVehiclesLeased
54 vehicle
evfm Lessee Operating Lease Number Of Vehicles Leased
LesseeOperatingLeaseNumberOfVehiclesLeased
70 vehicle
CY2019Q4 evfm Office Square Footage
OfficeSquareFootage
24474 sqft
CY2019Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q2 evfm Office Square Footage
OfficeSquareFootage
8816 sqft
CY2019Q2 evfm Adjustments To Additional Paidin Capital Reclassification Of Warrants
AdjustmentsToAdditionalPaidinCapitalReclassificationOfWarrants
6900000 USD
CY2019Q2 evfm Purchase Right Liability
PurchaseRightLiability
3200000 USD
CY2019Q2 evfm Loss On Issuance Of Purchase Rights
LossOnIssuanceOfPurchaseRights
700000 USD
evfm Periodic Release Of Security Deposit
PeriodicReleaseOfSecurityDeposit
5000 USD
evfm Periodic Release Of Security Deposit
PeriodicReleaseOfSecurityDeposit
66000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7198000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
160000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1728000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
197000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6425000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
466000 USD
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
186000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2192000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
998000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
563000 USD
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M9D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y3M
CY2020Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.12
CY2019Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.12
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
124000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
201000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2450000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
0 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2515000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2171000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1502000 USD
CY2019Q2 evfm Warrant Liability
WarrantLiability
3600000 USD
CY2019Q2 evfm Compensation Agreement Potential Bonus As A Percent Of Consulting Fees Earned
CompensationAgreementPotentialBonusAsAPercentOfConsultingFeesEarned
1
CY2015Q4 evfm Number Of Sublicenses
NumberOfSublicenses
2 Agreement
CY2019Q2 evfm Fair Value Adjustment Of Purchase Rights
FairValueAdjustmentOfPurchaseRights
19600000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10954000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
201000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2801000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8153000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
197000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
552000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
640000 USD
CY2019Q4 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
0 claim
CY2020Q3 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
0 claim
CY2019Q1 evfm Accrued Sublicense Fees
AccruedSublicenseFees
1300000 USD
CY2019Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3300000 USD
CY2019Q2 evfm Adjustments To Additional Paidin Capital Reclassification Of Purchase Rights Liability
AdjustmentsToAdditionalPaidinCapitalReclassificationOfPurchaseRightsLiability
22800000 USD
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10426107 shares
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.54
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10426107 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 evfm Short Swing Profit Disgorgement
ShortSwingProfitDisgorgement
0 USD
evfm Short Swing Profit Disgorgement
ShortSwingProfitDisgorgement
200000 USD
CY2020Q3 evfm Common Stock Reserved Upon Exercise Of Common Stock Warrants
CommonStockReservedUponExerciseOfCommonStockWarrants
10426107 shares
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
22989624 shares
CY2020Q1 evfm Stock Dividends Right
StockDividendsRight
1 shares
CY2020Q1 evfm Stock Dividend Rights Issued Per Share Of Common Stock Held
StockDividendRightsIssuedPerShareOfCommonStockHeld
1
CY2020Q1 evfm Class Of Warrant Or Right Vesting Term For Beneficial Ownership Threshold
ClassOfWarrantOrRightVestingTermForBeneficialOwnershipThreshold
P10D
CY2020Q1 evfm Class Of Warrant Or Right Right Agreement Beneficial Ownership Threshold
ClassOfWarrantOrRightRightAgreementBeneficialOwnershipThreshold
0.32
CY2020Q1 evfm Class Of Warrant Or Right Vesting Term
ClassOfWarrantOrRightVestingTerm
P10D
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1637000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2263000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11072000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6740000 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
631200 shares
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
290000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2873685 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
733000 shares

Files In Submission

Name View Source Status
0001618835-20-000242-index-headers.html Edgar Link pending
0001618835-20-000242-index.html Edgar Link pending
0001618835-20-000242.txt Edgar Link pending
0001618835-20-000242-xbrl.zip Edgar Link pending
amendmentno1toarlicens.htm Edgar Link pending
evfm-20200930.htm Edgar Link pending
evfm-20200930.xsd Edgar Link pending
evfm-20200930_cal.xml Edgar Link unprocessable
evfm-20200930_def.xml Edgar Link unprocessable
evfm-20200930_htm.xml Edgar Link completed
evfm-20200930_lab.xml Edgar Link unprocessable
evfm-20200930_pre.xml Edgar Link unprocessable
evfm-9302020ex311.htm Edgar Link pending
evfm-9302020ex312.htm Edgar Link pending
evfm-9302020ex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending